GU Cancer Clinical Trials

DISCLAIMER: All content found on cua.org is provided for information and education purposes. The medical information and clinical trials information is not intended to substitute for the advice of a physician, nor is it intended to provide legal advice. You should always consult your doctor for specific information on personal health matters, or other relevant professionals to ensure that your own circumstances are considered.

The CUA is not responsible in any manner for direct, indirect, special or consequential damages caused and/or arising from your use of cua.org.

Subspecialty
Renal | ON | Recruiting
RAPTOR
Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors (RAPTOR)
Turnstone Biologics, Corp. in collaboration with Takeda
Start Date: June 2, 2020

NCT #: NCT04301011

SPONSOR: Turnstone Biologics, Corp. in collaboration with Takeda

INFO:  https://clinicaltrials.gov/ct2/show/NCT04301011?recrs=abf&cond=Renal+Cell+Carcinoma&cntry=CA&draw=2&rank=28

CONTACT: Ottawa Hospital and Research Institute (OHRI): clinicalops@turnstonebio.com   

OTHER CANADIAN CENTRES:

Ottawa Hospital and Research Institute (OHRI): clinicalops@turnstonebio.com   

 

Prostate | AB, BC, MB, NB, NL, ON, QC, SK | Recruiting
PR22 (ANZUP 1801)
DASL-HiCaP: Darolutamide Augments Standard Therapy for Localized Very High-Risk Cancer of the Prostate. A Randomized Phase III Double-blind, Placebo-controlled Trial of Adding Darolutamide to Androgen Deprivation Therapy and Definitive or Salvage Radiation in Very High Risk, Clinically Localized Prostate Cancer
Dr. M. Tamin Niazi (JGH)
Start Date: March 31, 2020

NCT #: NCT04136353

INFO: https://clinicaltrials.gov/ct2/show/NCT04136353

CONTACT: (514) 340-8288

Bladder | AB, BC, ON, QC | Active, not recruiting
QBGJ398-302
Study of Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations
QED Therapeutics
Start Date: March 11, 2020

NCT #: NCT04197986

SPONSOR: QED Therapeutics, Inc. in collaboration with Helsinn Healthcare SA

INFO: https://clinicaltrials.gov/ct2/show/NCT04197986?recrs=abf&cond=Urothelial+Carcinoma&cntry=CA&draw=2&rank=2

CONTACT: 1-877-280-5655

OTHER CANADIAN CENTRES:

1. Cross Cancer Institute (Edmonton): 780-432-8762                                                     
2. BC Cancer (Vancouver): 604-877-6000                                                                          
3. Princess Margaret Cancer Centre (Toronto): 416-946-4501 x 2520                           
4. McGill University Health Centre (Montreal): 514-946-4501 x 2520                          
5. CHU de Québec Université Laval (Québec City): n/a       
 

Renal, Bladder | ON | Recruiting
IO-BREATHOMICS
Breathomics as Predictive Biomarker for Checkpoint Inhibitor Response
Dr. Geoffrey Liu
Start Date: February 24, 2020

NCT #: NCT04146064

SPONSOR: University Health Network

INFO: https://clinicaltrials.gov/study/NCT04146064

CONTACT: Sabine Schmid, MD

Tel.: 416-946-2000 x 5288                            

Email: sabine.schmid@uhn.ca

Other Canadian Centres:

Princess Margaret Cancer Centre (Toronto)  

Renal | ON | Recruiting
PERFORM
Preventing Toxicity in Renal Cancer Patients Treated With Immunotherapy Using Fecal Microbiota Transplantation
Dr. Ricardo Fernandes (Lawson Health Research Institute) - London
Start Date: January 23, 2020

NCT #: NCT04163289

SPONSOR:  Lawson Health Research Institute in Collaboration with Academic Medical Organization of Southwestern Ontario.

INFO:  https://clinicaltrials.gov/ct2/show/NCT04163289?recrs=abf&cond=Renal+Cell+Carcinoma&cntry=CA&draw=2&rank=2 

CONTACT:  519-685-8640

Renal | AB | Recruiting
AUR87A
AURORAX-0087A: GAG Scores for Surveillance of Recurrence in Leibovich Points ≥5 Non-metastatic ccRCC (AUR87A)
Elypta
Start Date: January 10, 2020

NCT #: NCT04006405

SPONSOR: Elypta

INFO: https://clinicaltrials.gov/ct2/show/NCT04006405?recrs=abf&cond=Renal+Cell+Carcinoma&cntry=CA&draw=2&rank=14

CONTACT: Canadian Investigator: Dr. Bimal Bhindi 403-943-8964

OTHER CANADIAN CENTRES: Prostate Cancer Centre (Calgary)

 

Prostate | QC | Recruiting
PICT-01
Biomarkers for Neoadjuvant Pembrolizumab in Non-Metastatic Prostate Cancer Positive by 18FDG-PET Scanning (PICT-01
Dr. Yves Fradet
Start Date: January 10, 2020

NCT#: NCT04009967

SPONSOR: CHU de Quebec-Universite Laval in collaboration with Merck Sharp & Dohme LLC

INFO: https://clinicaltrials.gov/ct2/show/NCT04009967

CONTACT: 418-525-4444 ext 15530

Prostate | ON | Recruiting
1234F
A Phase II Study of Durvalumab and Tremelimumab in Metastatic Castration-Resistant Prostate Cancer
Dr. Sebastien Hotte (JCC)
Start Date: December 27, 2019

CONTACT:

(604) 877-6000 Ext. 2746

Prostate | BC | Recruiting
1234E
A Phase II Study of Ipatasertib in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients with PI3K Pathway Alterations in Circulating Tumour DNA (ctDNA)
Dr. Kim Chi (Vancouver)
Start Date: December 27, 2019

CONTACT: 

(604) 877-6000 Ext. 2746

Renal | AB, BC | Recruiting
ATAGC05
Trifecta-Kidney cfDNA-MMDx Study
Philip F Halloran
Start Date: December 1, 2019

NCT #: NCT04239703

SPONSOR: University of Alberta

INFO: https://clinicaltrials.gov/study/NCT04239703

CONTACT: konrad@ualberta.ca

Other Canadian Centres:

1. University of Alberta (Edmonton)

2. St. Paul's Hospital (Vancouver)

The Canadian Urological Association (CUA) does not provide professional medical advice, diagnosis or treatment and cannot respond to requests for direct feedback, specific patient information or physician referrals. You should first always seek the advice of your urologist, physician and other qualified health provider with any questions regarding your medical condition. The contents of the CUA Website such as text, graphics, images, and other content are for informational purposes only. The content/information is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on the CUA website.

For comments or information, email Corporate.office@cua.org

Privacy Policy